Mechanisms of Reduced Maternal and Fetal Lopinavir Exposure in a Rat Model of Gestational Diabetes □ S by Gregory J Anger & Micheline Piquette-Miller
Mechanisms of Reduced Maternal and Fetal Lopinavir Exposure in
a Rat Model of Gestational Diabetes□S
Gregory J. Anger and Micheline Piquette-Miller
Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
Received May 13, 2011; accepted July 8, 2011
ABSTRACT:
Lopinavir (LPV) is the preferred HIV protease inhibitor in preg-
nancy, but it is unknown if gestational diabetes mellitus (GDM)
affects its disposition. Hepatic protein expression and plasma pro-
tein binding are altered in rodent models of GDM. Because LPV is
influenced by hepatic transporters and metabolic enzymes and is
highly protein bound, it was hypothesized that streptozotocin-
induced GDM would alter its disposition. Maternal and fetal tissues
were collected from GDM rats and controls 45 min after LPV
injection. In another cohort, fetuses were serially extracted 5 to 60
min after injection. LPV was quantified using liquid chromatogra-
phy tandem mass spectrometry. Expression of relevant transport-
ers, such as Multidrug resistance protein 1 (Mdr1), and cytochrome
P450 3a2 (Cyp3a2), which metabolizes LPV in rodents, was mea-
sured in maternal liver via quantitative reverse transcriptase poly-
merase chain reaction and Western blot analysis. Expression of
relevant transporters also was measured in placenta via quantita-
tive reverse transcriptase polymerase chain reaction. Protein bind-
ing was determined by ultrafiltration. Relative to controls, we ob-
served dramatically reduced maternal and fetal LPV exposure in
GDM. Compared with controls, maternal hepatic Mdr1 and Cyp3a2
were up-regulated, and protein binding was reduced in the GDM
group. Increased Mdr1- and Cyp3a2-mediated hepatobiliary clear-
ance, coupled with a larger unbound LPV fraction, is likely to have
facilitated hepatic elimination, thereby decreasing maternal and
fetal exposure. Not surprisingly, up-regulation of Mdr1 and
Cyp3a2’s transcriptional regulator, pregnane X receptor, was dem-
onstrated in maternal liver via Western blot analysis. Up-regulation
of Mdr1 in placentas isolated from the GDM group likely also
contributed to decreased fetal exposure to LPV. This study pro-
vides preclinical support for an as yet unreported drug-disease
(LPV-GDM) interaction.
Introduction
Antiretroviral drugs are administered to HIV-positive pregnant
women to prevent both maternal disease progression and vertical
HIV transmission. Lopinavir (LPV) coformulated with low-dose
ritonavir (RTV) is currently the preferred HIV protease inhibitor
combination for pregnant women because of superior efficacy and
extensive patient experience in pregnancy (http://aidsinfo.nih.gov).
As such, the majority of HIV-positive pregnant women in North
America now use LPV/RTV as part of their highly active antiret-
roviral therapy regimens. For LPV/RTV to be effective, optimal
LPV plasma concentrations must be maintained throughout gesta-
tion (Boffito et al., 2002; Masquelier et al., 2002).
Variation in LPV exposure has been observed with standard dosing
(Guiard-Schmid et al., 2003) and likely is caused by individual
variability in protein binding and drug transporter and metabolic
enzyme expression. LPV is a substrate for the multidrug resistance
protein 1 (MDR1) drug efflux transporter (Woodahl et al., 2005;
Agarwal et al., 2007) and is metabolized extensively by cytochrome
P450 3A4 (CYP3A4) (van Waterschoot et al., 2010). In the liver,
MDR1 facilitates LPV’s hepatobiliary excretion, whereas CYP3A4
converts it to increasingly hydrophilic metabolites (Fig. 1). Large
intersubject differences in the basal expression and activity of MDR1 and
CYP3A4 have been reported (Westlind-Johnsson et al., 2003; Meier et
al., 2006). In the placenta, MDR1 plays a barrier role by actively trans-
porting substrates back into systemic circulation. LPV is also highly
bound (99%) to blood proteins, including albumin and 1-acid glyco-
protein (AAG), so even small changes in binding result in large changes
in unbound drug fractions. Because only unbound drugs traverse cell
membranes, variation in LPV protein binding translates into deviations in
the efficiency with which LPV passes into maternal and fetal tissues.
Individual variability in these mechanisms can be introduced by a
variety of factors, including disease. Reports of drug disposition being
sensitive to disease have appeared in the literature for nearly 40 years
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(reviewed in Morgan et al., 2008); however, only in the last decade
have the effects of disease during pregnancy, including gestational
diabetes mellitus (GDM), been investigated (Wang et al., 2005;
Petrovic et al., 2008; Anger and Piquette-Miller, 2010). Studies indi-
cate that the prevalence of GDM in HIV-positive pregnant women far
exceeds that of HIV-negative pregnant women (Watts et al., 2004;
Kourtis et al., 2006; Martí et al., 2007; González-Tomé et al., 2008),
but to the best of our knowledge, it is unknown if this has an effect on
the disposition of highly active antiretroviral therapy drugs. In rats
with streptozotocin (STZ)-induced GDM, we have observed recently
that the plasma protein binding of the protease inhibitor saquinavir
decreases because of displacement by elevated lipids, whereas the
expression of hepatic Mdr1 and a variety of cytochrome P450 and
UDP-glucuronosyltransferase enzymes increases (Anger and Pi-
quette-Miller, 2010). In addition, altered disposition has been ob-
served for a variety of drugs in both nonpregnant humans with
diabetes (reviewed in Gwilt et al., 1991) and nonpregnant rats with
STZ-induced diabetes (reviewed in Lee et al., 2010).
In this study, maternal and fetal LPV exposure was examined in rats
with STZ-induced GDM and related to protein binding and hepatic
and placental drug transporter/metabolic enzyme expression data. In
terms of transporters, the expression of Mdr1 (encoded in rodents by
the Mdr1a and Mdr1b genes), multidrug resistance-associated protein
2 (Mrp2), and breast cancer resistance protein (Bcrp) was determined
in maternal liver and placenta. Mrp2 and Bcrp were included because
of documented interactions with LPV and/or other antiretroviral
drugs. In terms of metabolic enzymes, only Cyp3a2 was examined.
Whereas CYP3A4 is the dominant constitutive CYP3A subfamily
isoform in humans, Cyp3a2 is the dominant constitutive Cyp3a sub-
family isoform in rats (Nelson et al., 1993) and has been shown to
metabolize prototypical human CYP3A4 substrates such as verapamil
(Tracy et al., 1999; Choi and Burm, 2008; Hanada et al., 2008). Given
our previous findings with this model (Anger and Piquette-Miller,
2010), we hypothesized that maternal LPV exposure would be re-
duced. Our hypothesis regarding fetal LPV exposure was dependent
on whether protein binding or active feto-maternal transport domi-
nated LPV transfer (and whether placental Mdr1 was up-regulated).
Decreased protein binding could increase fetal LPV exposure by
facilitating materno-fetal placental transfer, but placental Mdr1 could
limit fetal exposure by actively transporting LPV in a feto-maternal
direction. Because the quantitative contribution of these processes
could change with time, we used a novel fetal sampling procedure to
FIG. 1. The dominant Cyp3a-mediated meta-
bolic pathway for LPV. LPV (A) is metabolized
to M3/M4 (B) (4-hydroxy-LPV) by Cyp3a, and
M3/M4 is metabolized subsequently to M1 (C)
(4-oxo-LPV), also by Cyp3a. Carbon-4 is the
location for these metabolic reactions, which is
indicated by an asterisk in A. LPV is a substrate
for MDR1. The M3/M4 and M1 metabolites are
likely substrates for MDR1.
1851LOPINAVIR EXPOSURE IN A RAT MODEL OF GESTATIONAL DIABETES
determine the time course of fetal exposure. Due to its role in Mdr1
and Cyp3a2 transcription (Lehmann et al., 1998; Tirona, 2011),
pregnane X receptor (PXR) expression in maternal liver also was
determined.
Our findings further advance our understanding of the impact that
GDM can have on drug disposition mechanisms and provide preclin-
ical support for an as yet unreported drug-disease (LPV-GDM) inter-
action. Effects associated with GDM would compound the drug
disposition effects that have been associated with pregnancy itself.
Materials and Methods
Pharmaceutical and Chemical Products. LPV and RTV were purchased
from USP (Rockville, MD) (PubChem Compound IDs 92727 and 392622).
LPV metabolites M1 and M3/M4 were purchased from Toronto Research
Chemicals, Inc. (North York, ON, Canada). Insulin glargine was purchased
from a commercial pharmacy in Toronto, ON (Sanofi-Aventis Canada, Inc.,
Laval, QC, Canada). Ethanol and methanol were purchased from Commercial
Alcohols (Brampton, ON, Canada) and Caledon (Georgetown, ON, Canada),
respectively. Unless otherwise noted, all of the other chemical products,
including STZ (PubChem Compound ID 5300), were purchased from Sigma-
Aldrich (St. Louis, MO). For intravenous administration, LPV was dissolved in
4:3:3 (v/v/v) ethanol/propylene glycol/5% dextrose in water (10 mg/ml).
Animals. Timed pregnant Sprague-Dawley rats (208–265 g on gestational
day 6) were purchased directly from Charles River Canada (Montreal, QC,
Canada) and housed individually in a temperature-controlled facility on a
12:12 h light/dark cycle. Rats were given free access to water and standard
chow (Harlan Teklad Global Diet 2018; Harlan Teklad, Madison, WI). Exper-
iments were approved by the Office of Research Ethics at the University of
Toronto and performed in accordance with Canadian Council on Animal Care
guidelines.
Animal Treatments/Monitoring and Tissue Collection. Rats were as-
signed randomly to one of three groups: nontreated diabetics (the GDM group),
vehicle controls (the vehicle group), and insulin-treated diabetics (the insulin-
treated group). On gestational day 6 (GD6), diabetes was induced by way of a
single subcutaneous injection of STZ in 0.1 M citrate buffer (pH 4.5) at a
dosage of 45 mg/kg. Vehicle control animals received a single subcutaneous
injection of citrate buffer on GD6. For all of the animals, body weight was
measured before respective injections (GD6) and then daily until sacrifice. For
animals in the GDM and vehicle groups, blood glucose was measured before
respective injections (GD6) and on GD7 to GD9, GD11, and GD20. For
animals in the insulin-treated group, blood glucose was measured before STZ
injection and then daily until sacrifice to determine daily insulin dosage
requirements. Blood glucose was measured at noon, in a nonfasted state, using
a typical glucometer with blood obtained via tail prick. When values exceeded
the range of this glucometer, a commercially available enzymatic glucose
assay was used according to the manufacturer’s instructions (Autokit Glucose;
Wako BioProducts, Richmond, VA). Mild hyperglycemia was defined as a
blood glucose concentration of 10 to 14 mM, and diabetes was defined as a
blood glucose concentration of 14 mM. For diabetic rats receiving insulin
treatment, treatment was initiated once diabetes was confirmed and consisted
of daily subcutaneous injections of insulin glargine as required. On GD20, one
cohort of animals (n  4–5 per group) received LPV (10 mg/kg i.v.) 45  1
min before being sacrificed to collect maternal blood (cardiac puncture) and
liver as well as up to 10 fetal compartments per dam. The location of each fetal
compartment within the uterine horn was noted (e.g., left versus right horn and
distance, in fetus number, away from the cervical stump). Amniotic fluid also
was collected from this first subset of animals. Aliquots of whole blood were
transferred to thrombin-coated BD Vacutainer tubes (BD Canada, Mississauga,
ON, Canada) and spun to collect serum. Samples were snap-frozen in liquid
nitrogen and stored at 80°C until use.
Sampling of Fetal Compartments for Time Course Determination. On
GD20, a second cohort of animals (n  3 per group) received LPV (10 mg/kg
i.v.) while anesthetized with continuous inhalation anesthesia (5% isoflurane
for induction and 1.5–2% isoflurane for maintenance) and was subjected
subsequently to sequential sampling of placentas and fetuses (collectively
referred to as fetal compartments) over a period of 1 h. After LPV adminis-
tration, a 3- to 4-cm midline abdominal incision was made so as to provide
access to the uterine horns via the intraperitoneal cavity. Five minutes postin-
jection, one of the uterine horns was externalized, and the most distal fetal unit
was identified. (Supplemental Fig. 1 illustrates fetal positioning within the
pregnant rat at approximately GD20.) The maternal vasculature supplying this
fetal unit’s placenta then was blocked via ligation to minimize both maternal
and fetal blood loss. Once the placental blood supply was blocked, the fetal
unit was removed through a small incision made in the uterine wall. The
remaining pups, still situated within the uterine horn, then were returned to the
maternal intraperitoneal cavity to await future time points. Additional fetal
compartments were collected from more proximal uterine horn positions and
from the unused uterine horn at 10, 15, 20, 30, 45, and 60 min postinjection.
Fetal compartments were not collected if their placental blood supply was
compromised during the collection of another fetal unit (e.g., if they shifted
position in such a way that their blood vessels sheared). After the collection of
the 60-min fetal unit, maternal blood (cardiac puncture) and liver were col-
lected. Throughout this procedure, maternal body temperatures were kept at
approximately 37°C using heating pads.
Determination of LPV and LPV Metabolite Concentrations. For the
preparation of samples and standards, a liquid-liquid extraction procedure was
adapted from Wang et al. (2006). In brief, serum and tissue samples were
thawed to room temperature. Tissues (maternal livers, placentas, and fetuses)
were homogenized in deionized water in glass tubes. For samples, 100 l of
serum or homogenate was added to tubes containing 20 ng of predried internal
standard (internal standard, RTV; final internal standard concentration, 200
ng/ml). For LPV standards, 100 l of drug-free serum or homogenate was
added to tubes containing both 20 ng of predried internal standard and 1 to 100
ng of predried LPV (final LPV standard concentrations, 10–1000 ng/ml). LPV
metabolites M1 and M3/M4 only were measured in maternal liver because the
placenta and fetus are not significant sites of LPV metabolism. For LPV
metabolite standards, 100 l of drug-free liver homogenate was added to tubes
containing internal standard as well as a combination of 1 to 100 ng of predried
LPV, M1, and M3/M4 (final standard concentration for each of LPV, M1, and
M3/M4, 10–1000 ng/ml). Fifty microliters of 500 mM Na2CO3 then was
added to the resulting samples and standards. After each tube was mixed by
vortex for 30 s, 1.2 ml of 1:1 (v/v) hexane/ethyl acetate was added. Mixtures
then were vortexed for 2 min to ensure complete extraction. The organic layer
was separated from the aqueous layer by centrifugation at 21,000g for 10 min
at 4°C. Seven-hundred microliters of the organic supernatant was transferred to
a fresh tube and dried under nitrogen gas. Extracts were reconstituted in 200
l of 80% methanol, vortexed for 30 s, and then centrifuged at 21,000g for 5
min at 4°C. Aliquots of the resulting extracts were transferred to autosampler
vials and stored at 4°C until 10 l could be injected into the liquid chromato-
graphic system. Through the use of concentration estimates obtained in pilot
experiments, serum and homogenates were diluted with volumes of deionized
water before processing so as to ensure that their concentrations fell within the
midrange of calibration curves.
LPV concentrations were determined using high-performance liquid chro-
matography tandem mass spectrometry (LC-MS/MS). The liquid chromato-
graphic system consisted of a CTC PAL autosampler (LEAP Technologies,
Carrboro, NC) and an Agilent Technologies (Santa Clara, CA) 1100 series
pump with a 50 mm  4.6 mm, 5 m, LiChrosorb RP-8 column (Phenomenex,
Torrance, CA), controlled at room temperature with a flow rate of 700 l/min.
Separation of LPV and internal standard was accomplished using isocratic
elution with 20:80 parts of 0.1% formic acid in water and 80% methanol. After
peak elution, the mobile phase was changed to 100% methanol to wash the
column. After sample injections, the syringe and injector valve each were
washed three times with methanol and three times with water. MS/MS was
performed on an API 4000 triple quadrupole mass spectrometer equipped with
a TurboIonSpray source operating in a positive ion multiple reaction monitor-
ing mode (Applied Biosystems/MDS Sciex, Foster City, CA). The multiple
reaction monitoring transitions were m/z 629.3 to 447.3 (declustering potential,
58 V; collision energy, 21 V) for LPV, m/z 645.3 to 447.3 (declustering
potential, 40 V; collision energy, 23 V) for M3/M4, m/z 643.3 to 447.2
(declustering potential, 80 V; collision energy, 23 V) for M1, and m/z 721.3 to
268.0 (declustering potential, 60 V; collision energy, 27 V) for RTV (the
internal standard). Source temperature was set to 500°C. Peak areas of LPV,
LPV metabolites, and the internal standard were determined using Analyst
software, version 1.4.2 (Applied Biosystems/MDS Sciex). For quantification,
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calibration curves were derived for each sample type by plotting the peak area
ratio (LPV or LPV metabolite peak area/internal standard peak area) of
standards against their concentrations. Linear regression equations with 1/x
weighting then were used to calculate sample LPV and/or LPV metabolite
concentrations. Across tissues, based on signal-to-noise ratios, the lower limit
of detection was 3 ng/ml, and the lower limit of quantification was 10
ng/ml.
ATPase Activation Assay. According to the manufacturer’s instructions,
rat Mdr1b PREDEASY ATPase kits (Solvo Biotechnology, Szeged, Hungary)
were used to determine whether LPV’s M3/M4 and M1 metabolites are
transported by rat Mdr1b. In brief, rat Mdr1b-expressing Sf9 membrane
vesicles were incubated in ATPase assay buffer [5 mM dithiothreitol, 0.1 mM
EGTA, 50 mM KCl, 10 mM MgCl2, 40 mM 3-(N-morpholino)propanesulfonic
acid-Tris (pH 7.0), and 4 mM sodium azide] containing 5 mM ATP and M1 or
M3/M4, at eight concentrations ranging from 0.14 to 300 M for M1 and 0.05
to 100 M for M3/M4 for 10 min at 37°C with and without 1.2 mM sodium
orthovanadate. Because it is an established Mdr1 substrate, LPV also was
assayed at eight concentrations ranging from 0.14 to 300 M. Specific Mdr1-
related ATPase activity was determined by calculating the difference in inor-
ganic phosphate liberation measured with and without 1.2 mM sodium or-
thovanadate (vanadate-sensitive ATPase activity). ATP-binding cassette
transporters such as Mdr1b are inhibited by sodium orthovanadate, so deter-
mining vanadate-sensitive ATPase activity distinguishes Mdr1-related ATPase
activity from the activity of other ATPases that are found in membrane
preparations.
Blood Chemistry. Determination of total cholesterol, high-density lipopro-
tein/low-density lipoprotein cholesterol, triglyceride, free fatty acid (FFA), and
albumin concentrations in serum was outsourced to the Banting and Best
Diabetes Centre, University of Toronto. Total cholesterol, high-density lipo-
protein/low-density lipoprotein cholesterol, triglyceride, and albumin concen-
trations were analyzed using an AutoAnalyzer and commercially available
reagents (Roche Diagnostics, Indianapolis, IN), whereas FFA was analyzed
using a commercially available ELISA kit (Wako Bioproducts). AAG concen-
trations were determined in-house using a commercially available, rat-specific
ELISA kit (GenWay, San Diego, CA), according to the manufacturer’s
instructions.
Polymerase Chain Reaction. In this study, Mdr1a/b, Mrp2, Bcrp, and
Cyp3a2 mRNA levels in maternal liver (n  4–5 dams per group) and
Mdr1a/b, Mrp2, and Bcrp mRNA levels in placenta (n  3 placentas per dam;
n  4–5 dams per group) were determined by quantitative reverse transcrip-
tase polymerase chain reaction (qRT-PCR). Total RNA was extracted from
tissue using the TRIzol method (Invitrogen, Carlsbad, CA), subjected to
quality and quantity measurements using a NanoDrop (Thermo Fisher Scien-
tific, Waltham, MA), and then reverse transcribed to cDNA via the First Strand
cDNA Synthesis Kit (MBI Fermentas, Hanover, MD), all according to the
manufacturer’s instructions. qRT-PCR was performed using LightCycler tech-
nology with SYBR Green I fluorescence detection (Roche Diagnostics). PCR
oligonucleotides were synthesized at The Hospital for Sick Children (DNA
Synthesis Centre, Toronto, ON, Canada), and their sequences have been
published previously (Petrovic et al., 2008). Expression levels were normalized
to 18S rRNA expression using the efficiency-corrected Ct method and
presented as a gene-to-18S ratio. The efficiency-corrected Ct method was
used because there were slight differences in the efficiencies of our primer sets.
Western Blot Analysis. Mdr1, Cyp3a2, and PXR.1 protein levels were
examined in maternal liver via Western blot analysis. Tissue samples first were
homogenized in radioimmunoprecipitation assay buffer (50 mM Tris-HCl, 150
mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, and 1% Triton X-100),
containing freshly added dithiothreitol (1 mM), phenylmethylsulfonyl fluoride
(0.5 mM), and 1 protease inhibitor cocktail (Sigma-Aldrich), using a mo-
torized pestle. Homogenates then were incubated on ice for 20 min and
subsequently centrifuged at 18,000g for 15 min. For each sample, the super-
natant was isolated and subjected to a Bradford assay (Bradford, 1976) to
determine total protein concentration. Samples containing 60 g (Mdr1), 20
g (Cyp3a2), or 50 g (PXR.1) of protein in Laemmli sample buffer were
heated at 36°C for 20 min (Mdr1) or 95°C for 5 min (Cyp3a2 and PXR.1) and
then separated via 8% (Mdr1) or 10% (Cyp3a2 and PXR.1) SDS-polyacryl-
amide gel electrophoresis and transferred to polyvinylidene fluoride mem-
branes (Bio-Rad Laboratories Canada, Ltd., Mississauga, ON, Canada). Mem-
branes were blocked in 5% fat-free milk powder at room temperature for 1 h
and incubated with mouse anti-Mdr1 (C219, 1:500, 1 mg/ml; Abcam, Inc.,
Cambridge, MA), rabbit anti-Cyp3a2 (ab78279, 1:1000, whole antiserum;
Abcam, Inc.), or goat anti-PXR.1 (A-20, 1:100, 0.2 mg/ml; Santa Cruz Bio-
technology, Inc., Santa Cruz, CA) antibodies at 4°C overnight on a rocker.
After a series of washes, membranes were incubated with a peroxidase-labeled
secondary antibody for 2 h at room temperature (goat anti-mouse at 1:3000 for
Mdr1, goat anti-rabbit at 1:10,000 for Cyp3a2, and donkey anti-goat at
1:10,000 for PXR.1; all from Jackson ImmunoResearch Laboratories, Inc.,
West Grove, PA). Immunoreactive proteins were detected in membranes using
ECL Plus (GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK) and
scanned using a FluorChem imaging system (Alpha Innotech, San Leandro,
CA). Through the use of AlphaEaseFC (version 6.0) software, also from Alpha
Innotech, the optical density (OD) of each band was determined. To confirm
equivalent protein loading after determining Mdr1, Cyp3a2, and PXR.1 band
ODs, a peroxidase-labeled anti--actin antibody was used (AC-15, 1:20,000, 2
mg/ml; Sigma-Aldrich). Mdr1, Cyp3a2, and PXR.1 ODs were normalized to
that of -actin. To correct for variability in gel transfer and other sources of
variation that affect Western blot quantification, a calibrator sample was
selected randomly from the vehicle group and run in each gel. Protein-to--
actin ratios for each blot were converted to percentages of that blot’s calibrator
sample ratio. For PXR.1 blots, 50 g of HeLa cell nuclear extract also was run
in each gel to provide a positive control (Santa Cruz Biotechnology, Inc.).
LPV Protein Binding Assay. LPV protein binding in rat serum was
determined by ultrafiltration with Amicon Ultra 0.5-ml centrifugal filter units
(molecular weight cutoff, 10,000; Millipore Canada, Ltd., Etobicoke, ON,
Canada). Serum samples from 4 to 5 dams per group, all with known serum
LPV concentrations, first were equilibrated for 30 min at 37°C. Then, 500 l
of each individual sample was transferred to centrifugal filter devices and
equilibrated for another 30 min at 30°C. After equilibration, samples were
centrifuged at 5000g for 5 min in a centrifuge maintained at 30°C. After this
initial spin, filtrates were collected and discarded (approximately 200 l).
Centrifugation then was continued with the remaining sample at 14,000g for 15
min, and filtrate samples were collected. LPV was extracted subsequently from
aliquots (100 l) of filtrate samples and quantified using LC-MS/MS as
described. Filtrate sample LPV concentrations then were compared with LPV
concentrations in corresponding unfiltered serum samples. Percentage un-
bound (% unbound) was determined using the following equation: % un-
bound  (Cfiltered/Cunfiltered)  100. Aweeka et al. (2010) validated the preci-
sion and accuracy of this method and found nonspecific binding of LPV to
centrifugal filter units to be very low.
Statistical Analysis. Data were analyzed using Prism 5 for Macintosh
(GraphPad Software, Inc., San Diego, CA). Concentration (e.g., LPV in serum
and tissues, lipids, albumin, etc.), transporter expression (mRNA and protein),
and protein binding (% unbound) data were analyzed using one-way analyses
of variance (ANOVAs) followed by Bonferroni posttests. To assess the effect
of uterine horn position on fetal exposure, all of the fetal concentrations were
converted to a percentage of their corresponding litter’s average concentration
and then subjected to one-way ANOVAs followed by Bonferroni posttests
(this was done within and across groups). To analyze blood glucose, body
weight, and some aspects of fetal exposure time courses, two-way ANOVAs
followed by Bonferroni posttests were performed. Fetal LPV area under the
concentration-versus-time curve (AUC0–60), Cmax, and Tmax values are pre-
sented as geometric group means, derived directly from the concentration-
versus-time curve using Prism 5’s area under curve analysis feature (trapezoi-
dal method). Linear regression was used to determine correlations (i.e., r2
values). Levels of significance for all of the statistical analyses were set at or
below   0.05, indicated as follows: /#, p  0.05; /##, p  0.01; and
/###, p  0.001. All of the results are presented as mean  S.D.
Results
Characterization of STZ-Induced GDM. All of the STZ-injected
rats developed at least mild hyperglycemia within 24 h and then
developed GDM (14 mM) by GD8. All of the animals in the GDM
group therefore were diabetic for 13 to 14 days before sacrifice on
GD20. Blood glucose concentrations in the GDM group, relative to
those of controls, were higher at GD8, GD11, and GD20 (p  0.001;
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Table 1). For the insulin-treated group, insulin treatment was initiated
when blood glucose concentrations first exceeded 14 mM and was
efficacious within hours. Blood glucose concentrations in the insulin-
treated group fluctuated but were significantly lower than values
obtained in the GDM group on GD11 and GD20 (p  0.01–0.001;
Table 1).
As expected during gestation, all of the animals gained weight
across the study duration; however, animals with GDM were lighter
than controls from GD8 until sacrifice (p  0.01–0.001; see Table 1
for GD11 and GD20 values). Animals in the vehicle group and
insulin-treated group did not differ in weight across the study duration
(p  0.05).
Blood chemistry data for animals with GDM revealed additional
characteristics that were consistent with unmanaged, or poorly man-
aged, GDM (Table 1). Hyperlipidemia was evident in the GDM group
because serum cholesterol (total), triglyceride, and FFA concentra-
tions were profoundly elevated (p  0.01–0.001). Polydipsia was
observed in the GDM group on GD16. In addition, compared with the
vehicle group, serum from animals in the GDM group contained
higher levels of AAG (p  0.01) and lower levels of albumin (p 
0.001). AAG concentrations in the insulin-treated group also were
elevated (p  0.01).
A number of fetal characteristics also were altered in the GDM
group (Table 1). First, litters were smaller in the GDM group at an
average of 11 pups per dam versus 16 in the vehicle group and 13 in
the insulin-treated group. Second, relative to controls, GDM fetuses
were smaller, whereas GDM placentas were larger. Consistent with
this, when the weight of each fetus was divided by the weight of its
placenta, the resulting ratios were found to be lower in the GDM
group compared with those in the vehicle (p  0.01) and insulin-
treated (p  0.05) groups. Finally, glucose concentrations in amniotic
fluid samples obtained from the GDM group were much higher than
those in samples from controls (p  0.05).
Maternal and Fetal LPV Exposure at 45 Minutes. Relative to
controls, LPV concentrations were lower in the GDM group’s serum
and tissue samples 45 min after administration (Table 2). Concentra-
tions in serum and tissue samples from the vehicle and insulin-treated
groups were not statistically different from each other (p  0.05).
Unbound LPV concentrations also were determined in 45-min mater-
nal serum samples. Unbound LPV concentrations were 11.7 ng/ml in
the GDM group compared with 12 and 12.8 ng/ml in the vehicle and
insulin-treated groups, respectively (p  0.05). When expressed as
percentages of total serum LPV concentrations, 1.6  0.8% of the
drug was unbound in the GDM group compared with 0.6  0.3 and
0.6  0.4% in the vehicle and insulin-treated groups, respectively
(p  0.05). LPV plasma protein binding in the rat has been shown to
be constant across a range of total LPV concentrations that encom-
passes all of the values observed in our study (Kumar et al., 2004).
When LPV concentrations in tissues were divided by corresponding
unbound LPV concentrations in maternal serum, significantly de-
creased ratios were observed in GDM maternal livers, placentas, and
fetuses (p  0.05; Fig. 2). This indicates that maternal and fetal
exposure in the GDM group is lower than that in controls even after
controlling for changes in protein binding.
Influence of Fetal Uterine Horn Position on Fetal LPV Expo-
sure. Position within the uterine horn was noted for all of the fetal
compartments that were sampled 45 min after administration (up to 10
positions, right horn 1–5 and left horn 1–5). After fetal concentrations
were converted to a percentage of their corresponding litter’s average
concentration, which corrects for variation in exposure between dams,
one-way ANOVA failed to detect a significant overall difference
between the position means (p  0.05). This was true across and
within this study’s three groups.
Time Course of Fetal LPV Exposure in GDM. Pups were re-
moved surgically from dams 5, 10, 15, 20, 30, 45, and 60 min after
LPV administration to generate a concentration-versus-time curve for
fetal exposure within each dam (Fig. 3). Although LPV concentrations
did not differ significantly until the 20-min time point, the overall time
course of fetal LPV exposure for each group did. From 5 to 30 min
postinjection, fetal concentrations in the vehicle group rose in a
manner consistent with the distribution of LPV from maternal circu-
lation (site of administration) to the fetal compartment. From 30 to 60
min postinjection, fetal concentrations in the vehicle group began to
fall in a manner consistent with the clearance of LPV from the fetal
compartment. In the GDM group, there was only one apparent phase
after the 5-min time point: a phase dominated by clearance. The Cmax
for LPV exposure in the GDM group occurred at the first time point
that was examined (5 min), and fetal concentrations continued to fall
thereafter. The insulin-treated time course exhibited both a distribu-
tion and a clearance phase, but the distribution phase lasted only 20
min. With respect to AUC0–60, fetuses in the vehicle group were
exposed to more LPV than fetuses in the GDM group (Table 3). The
TABLE 2
Maternal and fetal LPV concentrations 45 min after LPV administration
Drug concentrations were determined 45 min after LPV administration via LC-MS/MS.
Maternal results are from four to five dams per group, whereas placental and fetal results
represent four to five maternal means per group from five randomly selected placentas or
fetuses per dam.
Sample Vehicle GDM Insulin-Treated
Maternal serum (g/ml) 2.04  0.37 0.76  0.12*** 2.17  0.48###
Maternal liver (g/g) 47.5  16.6 14.4  6.02** 44.25  9##
Placenta (g/g) 2.45  0.93 0.83  0.34*** 2.36  1.1###
Fetus (g/g) 0.15  0.05 0.04  0.02*** 0.12  0.07###
Asterisks represent significant differences from vehicle controls, and pound signs represent
significant differences from GDM. **/##, p  0.01; ***/###, p  0.001.
TABLE 1
The effect of STZ-induced GDM, with and without insulin treatment, on various
physiological and biochemical characteristics
All of the results are presented as mean  S.D. Maternal results are from seven to eight
dams per group, whereas fetal results are from three to six randomly selected fetuses per
seven to eight dams per group (fetal body weight). Amniotic fluid data are from one pooled
sample per seven to eight dams per group.
Characteristic Vehicle GDM Insulin-Treated
Blood glucose
GD6 (mM) 6  0.9 6  0.4 6.5  1.3
GD11 (mM) 6.3  1 23.2  2.8*** 16  6.6***,##
GD20 (mM) 5.8  1.1 26.8  2.9*** 9.3  7.2###
Body weight
GD6 (g) 243  10 242  21 244  12
GD11 (% baseline) 116  1 103  2** 108  5
GD20 (% baseline) 154  6 136  7*** 152  1###
Blood chemistry (GD20)
Total cholesterol (mM) 1.9  0.3 8  4.7** 2.6  0.6##
High-density cholesterol
(mM)
1.1  0.5 0.9  0.3 1.3  0.7
Triglycerides (mM) 2.9  2.1 25.9  16.6*** 3.2  2.2##
FFAs (mEq/l) 1.1  1.2 7.6  6.8* 1.1  0.7#
AAG (g/ml) 49  8 87  30** 86  12**
Albumin (g/l) 34  4 18  7*** 36  4###
Water intake
GD16 ml/(kg/day)	 160  91 768  205*** 168  24###
Fetal characteristics (GD20)
Litter size 16  2 11  2** 13  3
Body weight (g) 2.59  0.14 2.29  0.24* 2.43  0.18
Placenta weight (g) 0.52  0.05 0.65  0.08** 0.5  0.08##
Fetus/placenta weight 5.1  0.6 3.6  0.6** 5  0.4#
Amniotic glucose (mM) 2.6  0.8 32.2  9*** 7.5  8.7###
Asterisks represent significant differences from vehicle controls, and pound signs represent
significant differences from GDM. */#, p  0.05; **/##, p  0.01; ***/###, p  0.001.
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insulin-treated group had an AUC0–60 that fell between values ob-
served in the vehicle and GDM groups (Table 3). Maternal serum and
liver concentrations were evaluated in this cohort at the 60-min time
point. Serum and liver LPV concentrations in the GDM condition
were lower than those of the vehicle and insulin-treated groups, which
did not differ from each other (Table 3).
Drug Transporter and Cyp3a2 Expression in GDM. The expres-
sion of Mdr1a/b, Mrp2, Bcrp, and Cyp3a2 mRNA was determined in
maternal liver, and the expression of Mdr1a/b, Mrp2, and Bcrp mRNA
was determined in placenta (Fig. 4). In maternal liver, both Mdr1b and
Cyp3a2 were up-regulated significantly in the GDM group. Hepatic
Mdr1b/18S standard ratios were 3.55  2 in the GDM group com-
pared with 0.33  0.41 in the vehicle group (p  0.05) and 0.26 
0.16 in the insulin-treated group (p  0.05). Hepatic Cyp3a2/18S
standard ratios were 1  0.35 in the GDM group compared with
0.43  0.04 in the vehicle group (p  0.05) and 0.55  0.22 in the
insulin-treated group (p  0.05).
Significant mRNA findings in maternal liver were confirmed at the
level of protein (Fig. 5). Hepatic Mdr1/-actin standard ratios (%
calibrator) were 149  41 in the GDM group compared with 92  6
in the vehicle group (p  0.05) and 85  6 in the insulin-treated
group (p  0.05). Hepatic Cyp3a2/-actin standard ratios (% cali-
brator) were 170  63 in the GDM group compared with 78  27 in
the vehicle group (p  0.05) and 64  14 in the insulin-treated group
(p  0.05). Hepatic Mdr1a and Cyp3a2 protein concentrations cor-
related well with corresponding Mdr1a (r2  0.9; p  0.001) and
Cyp3a2 (r2  0.56; p  0.01) mRNA concentrations.
In placenta, both Mdr1b and Bcrp were up-regulated significantly
in the GDM group. Placental Mdr1b/18S standard ratios were 1.9 
0.43 in the GDM group compared with 0.95  0.18 in the vehicle
group (p  0.01) and 1.06  0.39 in the insulin-treated group (p 
0.05). Placental Bcrp/18S standard ratios were 2.49  0.96 in the
GDM group compared with 1.08  0.27 in the vehicle group (p 
0.05) and 1.45  0.64 in the insulin-treated group (p  0.05).
Significant mRNA findings in placenta were not confirmed at the
level of protein due to insufficient sample volume. Intraplacental
TABLE 3
Pharmacokinetic parameters derived from concentration-versus-time curves for
fetal LPV exposure
AUC0–60, Cmax, and Tmax values as well as maternal serum and liver values are arithmetic
groups means. Maternal samples were collected at 60 min.
Parameter Vehicle GDM Insulin-Treated
Fetal time course
AUC0–60 (g  min/g) 15.63  1.21 4.76  0.77*** 9.03  1.29***
,###
Cmax (g/g) 0.37  0.06 0.16  0.05** 0.21  0.02*
Tmax (min) 27  6 8  6* 13  8
Maternal samples
Serum LPV	 (g/ml) 2.17  0.32 0.62  0.32** 1.44  0.38
Liver LPV	 (g/g) 47.39  15.83 9.13  7.12* 42.76  15.37#
Asterisks represent significant differences from vehicle controls, and pound signs represent
significant differences from GDM. */#, p  0.05; **, p  0.01; ***/###, p  0.001.
FIG. 2. Tissue/unbound maternal serum LPV concentration ratios. LPV concentra-
tions in maternal livers (A), placentas (B), and fetuses (C) were standardized to
unbound concentrations in maternal serum. Resulting ratios are presented as
mean  S.D. Maternal liver results are from four to five dams per group. Placental
and fetal results are from five randomly selected placentas or fetuses per dam, and
there were four to five dams per group (n  20–25 data points per group). Asterisks
represent significant differences from vehicle controls, and pound signs represent
significant differences from GDM. /###, p  0.001.
FIG. 3. Time course of fetal exposure to LPV after intravenous maternal adminis-
tration. Pups were removed surgically from dams 5, 10, 15, 20, 30, 45, and 60 min
after administration to generate a concentration-versus-time curve for fetal LPV
exposure. All of the results are presented as mean  S.D. Asterisks represent
significant differences from vehicle controls, and pound signs represent significant
differences from GDM. /#, p  0.05; , p  0.01; , p  0.001.
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correlations were observed between Mdr1a and Mdr1b, Mdr1b and
Mrp2, Mdr1b and Bcrp, and Mrp2 and Bcrp (p  0.0001).
With respect to the expression of all of the genes and proteins
examined in this study, we did not find a difference between the
vehicle and the insulin-treated groups (p  0.05).
LPV Metabolite Formation in Maternal Liver at 45 min. When
metabolite concentrations were divided by corresponding LPV con-
centrations, there was a trend toward decreased M3/M4 ratios (p 
0.05 but p  0.05 for Bonferroni posttests; Fig. 6A) and increased M1
ratios (p  0.01 but p  0.05 for Bonferroni posttests; Fig. 6C).
However, when M1, a secondary metabolite, was divided by corre-
sponding M3/M4 concentrations, the metabolite from which it is
formed, a significant increase in M1 ratios was observed in the GDM
group (p  0.001; Fig. 6B). Decreased M3/M4-to-LPV ratios with
increased M1-to-M3/M4 ratios are indicative of increased M3/M4
metabolism to M1, a process mediated by Cyp3a2. Absolute com-
bined LPV and metabolite concentrations (i.e., [LPV]
 [M3/M4] 

[M1]) were 30  13 in the GDM group compared with 176  77 in
the vehicle group (p  0.05) and 182  122 in the insulin-treated
group (p  0.05). ATPase activation assays were performed with the
M1 and M3/M4 metabolites, but the results were somewhat incon-
clusive. In these assays, ATPase activity briefly rose but then fell
below baseline (G. J. Anger, unpublished observations). Mdr1 has
basal ATPase activity, and depression of this activity is observed with
slowly transported substrates. In support of this, LPV produced a
similar pattern of ATPase activity, and it is an established Mdr1
substrate.
Hepatic PXR.1 Protein Expression in GDM. Hepatic PXR.1
protein levels were examined due to its integral role in the regulation
of both Mdr1 and Cyp3a2. As Fig. 7 illustrates, the expression of
hepatic PXR.1 in the GDM group was substantially higher than that in
control groups. Hepatic PXR.1/-actin standard ratios (% calibrator)
were 309  55 in the GDM group compared with 75  33 in the
vehicle group (p  0.001) and 96  14 in the insulin-treated group
(p  0.001). There was a significant correlation between hepatic
PXR.1 protein concentrations and hepatic concentrations of both
Mdr1 (r2  0.64; p  0.001) and Cyp3a2 (r2  0.43; p  0.01).
Discussion
Experimental GDM had a significant impact on maternal and fetal
LPV exposure in this study. Total LPV concentrations in serum from
dams with GDM were less than half of control values. Although
unbound serum concentrations were roughly equivalent in all of the
groups, they represented a greater percentage of total serum concen-
trations in the GDM group. We have demonstrated previously that
GDM-induced hyperlipidemia in rats, which was observed in this
study (Table 1) and is observed clinically in GDM (Wiznitzer et al.,
2009), leads to drug displacement (Anger and Piquette-Miller, 2010).
Albumin concentrations in GDM also were reduced significantly,
which means there were fewer LPV binding sites. As stated previ-
ously, decreased protein binding facilitates the passage of LPV into
eliminating organs and the fetal compartment.
LPV is eliminated from the body primarily by hepatobiliary excre-
tion. In a study of LPV metabolism and disposition in the rat, 69.5%
of an intravenous LPV dose was recovered in bile after 24 h and
approximately 86% of this occurred in the first 2 h (Kumar et al.,
2004). In maternal liver, at 45 and 60 min, LPV concentrations in
GDM were less than one third of control values. Moreover, when
hepatic LPV concentrations in our study were standardized to un-
bound serum concentrations, lower values still were observed in the
GDM group. This suggests that more rapid clearance of LPV from
liver tissue occurred in the GDM group. Significantly higher hepatic
Mdr1 and Cyp3a2 expression in the GDM group supports this. Func-
tionally, data supporting enhanced hepatic metabolism of the M3/M4
primary metabolites to the M1 secondary metabolite were obtained in
GDM livers. The human equivalent of Cyp3a2, CYP3A4, is the
principle determinant of LPV pharmacokinetics in humans. In fact,
LPV is coformulated with RTV specifically for its ability to inhibit
CYP3A enzymes and thereby increase LPV exposure (Abbott Labo-
ratories Ltd., 2010). However, it has been proposed by van Water-
schoot et al. (2010) that hepatic Mdr1 and Cyp3a work in a coordi-
nated fashion to eliminate LPV in mice. More specifically, it has been
proposed that Cyp3a drastically lowers LPV concentrations so as to
prevent the saturation of Mdr1-mediated hepatobiliary excretion.
Agarwal et al. (2007) provided evidence supporting the in vitro
saturability of Mdr1 by LPV when they observed transporter activity
at low LPV concentrations (0.5 M) but not at high LPV concentra-
tions (5–25 M). Data from our study indicate that LPV metabolites
also could contribute to Mdr1 saturation. By monitoring ATPase
activity, we demonstrated that the M3/M4 and M1 metabolites interact
with rat Mdr1 in a manner similar to LPV. That said, the fact that
absolute combined LPV and metabolite concentrations were much
lower in GDM livers suggests that both Mdr1-mediated efflux and
Cyp3a2-mediated metabolism contributed to enhanced hepatobiliary
FIG. 4. Drug transporter and Cyp3a2 mRNA expression in GDM.
The mRNA expression of Mdr1a/b, Mrp2, Bcrp, and Cyp3a2 in
maternal liver (left bars) and Mdr1a/b, Mrp2, and Bcrp in placenta
(right bars) was determined by qRT-PCR. All of the results are
presented as a percentage of the vehicle group’s mean  S.D.
Maternal liver results are from four to five dams per group, whereas
placental results represent four to five maternal means per group
from three randomly selected fetuses per dam. All of the results are
presented as mean  S.D. Asterisks represent significant differ-
ences from vehicle controls, and pound signs represent significant
differences from GDM. /#, p  0.05; , p  0.01.
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clearance of LPV and its metabolites in GDM (Abbott Laboratories
Ltd., 2010).
Although the specific reason for the observed pharmacokinetic
findings in the GDM group dams has not been fully established, it is
clear that important mechanisms have been altered. In addition to the
above speculation regarding hepatic elimination, it is plausible that
there was a contribution from increased renal elimination. In nonpreg-
nant individuals, approximately 10.4  2.3% of a LPV dose is
recovered in urine after 8 days (Abbott Laboratories Ltd., 2010).
Urinary output dramatically increases in STZ-induced diabetes as a
result of osmotic diuresis (Anger et al., 2009; Anger and Piquette-
Miller, 2010). Although urinary output was not measured in this
study, water intake was nearly 5-fold higher in the GDM group than
that in controls (Table 1), and a strong positive correlation exists
between urinary output and water intake (G. J. Anger, unpublished
observations).
To better assess fetal exposure, LPV concentrations were deter-
mined in placentas and fetuses at 45 min and in fetuses from a second
cohort at multiple time points. At 45 min, LPV concentrations were
significantly lower in the GDM group. It stands to reason that reduced
fetal exposure in the GDM group was largely the result of reduced
maternal exposure. Because maternal serum LPV levels were much
lower in the GDM group, less LPV would have been available for
placental transfer; however, when placental and fetal LPV concentra-
tions were standardized to unbound LPV concentrations in maternal
serum, ratios in the GDM group were still lower than control ratios.
FIG. 5. Hepatic Mdr1 and Cyp3a2 protein expression in GDM. Mdr1 and Cyp3a2
protein concentrations were determined in maternal liver via Western blot analysis.
A, representative blots showing Mdr1, Cyp3a2, and -actin expression in samples
from each group. B an C, quantified Mdr1 (B) and Cyp3a2 (C) results are presented
as mean percentages of a calibrator sample’s values  S.D. and are from four to five
dams per group. All of the results are presented as mean  S.D. Asterisks represent
significant differences from vehicle controls, and pound signs represent significant
differences from GDM. /#, p  0.05.
FIG. 6. Standardized concentration ratios for LPV metabolites in maternal liver 45
min after LPV administration. Forty-five minutes after LPV administration, LPV
and LPV metabolite concentrations were determined in maternal liver samples via
LC-MS/MS. A, because M3/M4 is a product of LPV (i.e., a primary metabolite),
concentrations of M3/M4 were standardized to LPV concentrations. B, because M1
is a product of M3/M4 (i.e., a secondary metabolite), concentrations of M1 were
standardized to M3/M4 concentrations. C, M1 concentrations also were standard-
ized to LPV concentrations. All of the results are presented as mean  S.D. of four
to five dams per group. All of the results are presented as mean  S.D. Asterisks
represent significant differences from vehicle controls, and pound signs represent
significant differences from GDM. /##, p  0.01.
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This suggests that LPV also was being actively excluded from the
fetal compartment. This is likely attributable to placental efflux, and
this hypothesis is supported by increased Mdr1b mRNA expression in
GDM placentas.
The time courses of fetal exposure for both vehicle and insulin-
treated groups exhibited an accumulation phase, whereas the GDM
group’s time course did not. Accordingly, fetuses in the vehicle and
insulin-treated groups were exposed to more LPV than fetuses in the
GDM group. In the absence of placental transporter data, this finding
would be surprising given the GDM group’s decreased albumin
concentrations and decreased LPV protein binding. Studies using the
human cotyledon perfusion model have shown that albumin plays a
major role in placental LPV transfer (Gavard et al., 2006; Ceccaldi et
al., 2010). For example, Gavard et al. (2006) demonstrated that LPV
transfer was 23.6  6.9% at an albumin concentration of 2 g/l, 20.7 
10% at 10 g/l, and only 3.3  0.5% at 40 g/l. The data of Gavard et
al. (2006) predict higher transfer in our GDM group (15%) than that
in our control groups (6–7%), which is not what we observed.
The role of fetal exposure to antiretrovirals in the prevention of
vertical HIV transmission is not fully established, but it is generally
acknowledged that exposure is desirable. The concentration of pro-
tease inhibitors in human cord blood after in utero exposure is low but
varies greatly by molecule (Mirochnick et al., 2002; Chappuy et al.,
2004). Although the protease inhibitors RTV, indinavir, and saquina-
vir have low cord blood-to-maternal blood ratios that range from 0 to
0.01 (Chappuy et al., 2004), LPV has been found to have a compar-
atively high ratio of 0.2  0.13 (Stek et al., 2006). More importantly,
Gavard et al. (2006) demonstrated in the human cotyledon perfusion
model that this ratio leads to fetal compartment concentrations that
exceed the 50% HIV inhibitory concentration for LPV under normal
physiological conditions (Abbott Laboratories Ltd., 2010). The fact
that fetal exposure was reduced in STZ-induced GDM raises ques-
tions about GDM’s potential impact on vertical HIV transmission risk
and could warrant clinical investigation.
Induction of Mdr1 and Cyp3a has been observed in tissues from
male rats with STZ-induced diabetes (Maeng et al., 2007; Kameyama
et al., 2008; Hasegawa et al., 2010), but reports in female rats with
STZ-induced diabetes or STZ-induced GDM are limited (Mulay and
Varma, 1984; Anger et al., 2009; Anger and Piquette-Miller, 2010).
We posit that disruptions to lipid and glucose homeostasis underlie the
alterations to drug transporter and Cyp3a2 expression that were ob-
served in STZ-induced GDM. In brief, it is known that drug trans-
porters and metabolic enzyme transcription is controlled by several
nuclear receptors, such as PXR, which can be activated themselves by
lipids and glucose (Handschin and Meyer, 2005). We have demon-
strated previously that nuclear receptor networks with roles in the
regulation of hepatic drug transporters and metabolic enzymes are
activated in STZ-induced GDM (Anger and Piquette-Miller, 2010). In
this study, we observed a significant up-regulation in the PXR.1
isoform in GDM livers. PXR is Mdr1 and Cyp3a2’s primary tran-
scriptional regulator, so not surprisingly, its hepatic protein concen-
trations positively correlated with hepatic Mdr1 and Cyp3a2 concen-
trations. It is conceivable that a similar regulatory effect may be at
work in the placenta, although recent work with PXR knockout mice
has drawn the role of placental PXR in placental transporter regulation
into question (Gahir and Piquette-Miller, 2011).
Although this study focused on LPV, the disposition of other drugs
would likely be altered in experimental GDM. Protein binding aside,
many drugs that are used today are substrates for MDR1 and/or BCRP
(Chandra and Brouwer, 2004), and CYP3A4 is believed to be in-
volved in the metabolism of approximately half of all drugs
(Guengerich, 1999). Relating this to anti-HIV therapy, LPV is taken
typically with other anti-HIV drugs, and most of these drugs are
substrates for at least one of MDR1, BCRP, and CYP3A4 (reviewed
in Kis et al., 2010). For example, zidovudine/azidothymidine and
lamivudine/2,3-dideoxy-3-thiacytidine are BCRP substrates and of-
ten are taken alongside LPV/RTV in pregnancy (Kis et al., 2010).
In conclusion, our findings demonstrate that maternal and fetal LPV
exposure is reduced in a rat model of GDM. For maternal exposure,
our data suggest that PXR-mediated hepatic Mdr1 and Cyp3a2 up-
regulation and decreased protein binding are responsible. Enhanced
renal elimination in GDM also may contribute but was not evaluated
directly. For fetal exposure, our data suggest that although fetal
exposure is dictated largely by maternal exposure, increased placental
transporter expression in GDM serves to further limit placental trans-
fer. Through the use of a novel sampling procedure to characterize
fetal exposure, it was determined that GDM fetuses accumulated very
little LPV. This study further advances our understanding of the
impact that GDM can have on drug disposition mechanisms and
provides preclinical support for an as yet unreported drug-disease
(LPV-GDM) interaction. If confirmed in humans, the effects reported
in this study would need to be considered when exposure targets are
not met in GDM pregnancies. Studies using the clinical formulation of
LPV are underway and will determine whether the effects described in
this study persist in the presence of RTV.
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